What is NDC 70954-774?

70954-774 is the product NDC for Everolimus, Everolimus 3 mg/1 tablet, for suspension, listed with the FDA by ANI Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

ANI Pharmaceuticals, Inc., NDC labeler code 70954. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Everolimus?

67 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Everolimus NDC 70954-774 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70954-774Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70954-0774Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70954-774-20	70954077420	28 BLISTER PACK in 1 CARTON (70954-774-20) / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (70954-774-10)Marketed from Oct 10, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — 3 mg/1
Dosage form: Tablet, For suspension
Route: Oral
Labeler: ANI Pharmaceuticals, Inc.NDC labeler code 70954
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 220597
Marketing start: Oct 10, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 70954-774_ed7f01b0-3660-4785-a057-a32eea78d64bSPL ID ed7f01b0-3660-4785-a057-a32eea78d64b
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470954077420 followed by a unit qualifier and the quantity

Package 70954-0774-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 70954-774

What is NDC 70954-774?: 70954-774 is the product NDC for Everolimus, Everolimus 3 mg/1 tablet, for suspension, listed with the FDA by ANI Pharmaceuticals, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Everolimus.
What is the active ingredient?: Everolimus.
Who is the labeler?: ANI Pharmaceuticals, Inc., NDC labeler code 70954. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Everolimus?: 67 other product NDCs are listed under this name. See all Everolimus NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Everolimus NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Everolimus	Everolimus .25 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-003	72319-0003-0272319-0003-60
Everolimus	Everolimus .5 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-015	72319-0015-0272319-0015-60
Everolimus	Everolimus .75 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-016	72319-0016-0272319-0016-60
Everolimus	Everolimus 1 mg/1	TabletOral	i3 Pharmaceuticals, LLC	72319-017	72319-0017-0272319-0017-60
everolimus	Everolimus 2.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-030	82293-0030-1082293-0030-2182293-0030-31
everolimus	Everolimus 5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-031	82293-0031-1082293-0031-2182293-0031-31
everolimus	Everolimus 7.5 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-032	82293-0032-1082293-0032-2182293-0032-31
everolimus	Everolimus 10 mg/1	TabletOral	Novugen Pharma (USA) LLC.	82293-033	82293-0033-1082293-0033-2182293-0033-31
everolimus	Everolimus .25 mg/1	TabletOral	Aurobindo Pharma Limited	59651-931	59651-0931-60
everolimus	Everolimus .5 mg/1	TabletOral	Aurobindo Pharma Limited	59651-932	59651-0932-60

All 68 Everolimus NDCs

Other NDCs under ANDA 220597

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 220597
Product	Strength	Form · route	Labeler	Product NDC
Everolimus	Everolimus 2 mg/1	Tablet, For suspensionOral	ANI Pharmaceuticals, Inc.	70954-773
Everolimus	Everolimus 5 mg/1	Tablet, For suspensionOral	ANI Pharmaceuticals, Inc.	70954-775